GeoVax Labs

GeoVax reported Q3 2025 revenue of $2.5 million, down from $3.1 million a year earlier. Research and development expenses were reduced from $7.4 million to $5 million, the nine-month net loss rose slightly to $17 million, and cash on hand fell to $5 million. The stock lost 5.8% in regular trading and recovered 1.1% in after-hours trading. The company plans clinical trials for the GEO‑MVA vaccine, further development of the COVID‑19 vaccine CM04S1, expansion of MVA production and growth of its oncology program Gadeptin. » Plus sur de.investing.com

At the Emerging Growth Conference, GeoVax presented data showing its COVID-19 vaccine GEO-CM04S1 produced a stronger immune response in immunocompromised patients than a Pfizer vaccine. The company plans to raise an additional $12–15 million by year-end to further finance programs for COVID-19, mpox/pox and cancer. GeoVax emphasizes ongoing engagement with the FDA despite staffing shortages and hopes to capitalize on increased investor interest following an acquisition by Bavarian Nordic; analysts see a share-price range of $5–12 per share. » Plus sur de.investing.com

GeoVax Labs presented at an investor conference its three prioritized programs: GEO‑MVA against mpox/smallpox, GEO‑CM04S1 against COVID‑19 for immunocompromised patients, and Gedeptin for solid tumors. The EMA granted an accelerated development pathway for GEO‑MVA, making revenue within three years appear possible. Clinical data indicate better efficacy of GEO‑CM04S1 in certain immunocompromised patients compared with a competitor, and three phase‑2 studies are underway. The company is optimizing manufacturing with a continuous cell‑line platform for faster and more cost‑efficient vaccine production. » Plus sur de.investing.com